StockData

Halozyme Therapeutics vs Moderna

HALO and MRNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HALO and MRNA compare

Moderna is the larger company, worth 7.6 times as much as Halozyme Therapeutics ($82.6B against $10.9B).

Halozyme Therapeutics grew revenue faster over the last twelve months (41.2% versus −27.6% for Moderna).

Halozyme Therapeutics keeps more of each dollar of sales as profit, with a net margin of 24.9% compared with −141% at Moderna.

Halozyme Therapeutics scores higher on the StockData Score (13 against 5 for Moderna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHALOMRNA
Size and price
Market cap$10.9B$82.6B
Share price$95.97$206.80
Change, 1 year37.0%735%
Change, 5 years184%−37.3%
Beta (5Y)0.82−0.29
Employees4234,700
StockData Score
Total score13 (better)5
Valuation score00
Growth score4 (better)1
Performance score5 (better)1
Health score4 (better)3
Dividend score00
Valuation
P/E28.3×–
P/S6.5× (better)37.1×
P/B75.9×12.2× (better)
EV/EBITDA21.0×–
P/FCF13.5×–
PEG1.34–
FCF yield7.4% (better)−1.5%
Fair value$69.98$32.48
Margin of safety−37.1% (better)−537%
Growth
Revenue growth (TTM)41.2% (better)−27.6%
Revenue growth, 5Y average39.2% (better)19.3%
Net income growth (TTM)−25.8%–
EPS growth (TTM)−22.4%–
EPS growth, 5Y average23.0%–
Profitability
Gross margin82.4% (better)23.4%
Operating margin35.9% (better)−149%
Net margin24.9% (better)−141%
FCF margin48.5% (better)−55.8%
Return on equity174% (better)−39.0%
Return on invested capital21.7% (better)−80.9%
Financial health
Debt / equity14.950.09 (better)
Net debt / EBITDA3.24–
Interest coverage29.4×–
Current ratio2.71 (better)2.29
Altman Z-score4.4512.01 (better)
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions109%79.9%
Held by insiders1.3%5.6%
Insider net buying, 12 months−$49.8M (better)−$81.6M
Short interest, % of float12.2%8.8%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.